Experimental Cell Research, Год журнала: 2019, Номер 382(2), С. 111487 - 111487
Опубликована: Июнь 28, 2019
Язык: Английский
Cancer Letters, Год журнала: 2020, Номер 490, С. 174 - 185
Опубликована: Июль 25, 2020
T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis inhibit responses in various diseases, including cancer. Proportions of Tregs the peripheral blood some cancer patients increase by approximately two-fold, compared to those healthy individuals. contribute development progression suppressing effector cell functions, thereby compromising tumor killing promoting growth. Highly immunosuppressive express upregulated levels transcription factor, Forkhead box protein P3 (FoxP3). Elevated FoxP3+ within microenvironment (TME) showed a positive correlation with poor prognosis patients. Despite success immunotherapy, use checkpoint inhibitors, significant proportion show low response rates as result primary or acquired resistance against therapy. Some mechanisms which underlie therapy are associated Treg suppressive function. In this review, we describe contribution development/progression, Treg-mediated immunosuppression. We discuss prognostic significance different cancers their potential biomarkers. also therapeutic strategies target combination other types immunotherapies aiming overcome improve clinical outcomes Overall, understanding could help more effective targeted enhance
Язык: Английский
Процитировано
255
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 1156 - 1156
Опубликована: Янв. 29, 2025
Gastric cancer (GC) ranks as the fifth most prevalent malignant neoplasm globally, with an increased death rate despite recent advancements in research and therapeutic options. Different molecular subtypes of GC have distinct interactions immune system, impacting tumor microenvironment (TME), prognosis, reaction to immunotherapy. Tumor-infiltrating lymphocytes (TILs) TME are crucial for preventing growth metastasis, evidenced by showing that patients who a significant density TILs better survival rates. But cells evolved variety mechanisms evade surveillance, both sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) Programmed Death-Ligand 1 (PD-L1) playing pivotal role development immunosuppressive TME. They prevent T cell activation proliferation resulting decrease system’s capacity recognize eliminate cells. These checkpoint molecules function via different but complementary mechanisms, expression Siglec-15 being mutually exclusive PD-L1 and, therefore, providing approach. The review explores how affect patient outcomes GC, particular emphasis on their within potential targeting pathways
Язык: Английский
Процитировано
1
Brazilian Journal of Biology, Год журнала: 2025, Номер 85
Опубликована: Янв. 1, 2025
Abstract Breast cancer is the leading cause of cancer-related mortality among women worldwide. The development predictive biomarkers and immunologic markers has revolutionized breast diagnosis treatment, enabling personalized medicine approaches. This study aims to review current status, challenges, future directions in cancer. Predictive such as HER2/neu expression, estrogen receptor (ER)/progesterone (PR) genomic signatures play a crucial role treatment decisions, particularly for hormone receptor-positive HER2-positive tumors. Immunologic markers, including PD-L1 microsatellite instability (MSI), tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), are essential predicting responses immunotherapy, especially aggressive subtypes like triple-negative (TNBC). However, challenges heterogeneity, therapy resistance, standardization biomarker testing remain significant barriers. also explores emerging technologies artificial intelligence (AI), profiling, liquid biopsy, which expected enhance precision medicine, improve early diagnosis, optimize strategies. integration these advanced molecular approaches holds great promise improving patient outcomes overcoming existing limitations management.
Язык: Английский
Процитировано
0
Journal of Gastrointestinal Surgery, Год журнала: 2019, Номер 24(1), С. 28 - 38
Опубликована: Окт. 17, 2019
Язык: Английский
Процитировано
16
Chinese Clinical Oncology, Год журнала: 2023, Номер 12(5), С. 54 - 54
Опубликована: Сен. 11, 2023
Despite considerable international heterogeneity in the incidence and histological subtypes of gastric cancer (GC), addition to more recent epidemiological trends, chemotherapy has long represented main systemic therapeutic option its treatment. For roughly 20% GC with human epidermal growth factor receptor 2 (HER2) overexpression, there is a recently established role for HER2+ based therapy form trastuzumab. However, while immune checkpoint inhibitors (ICIs) have revolutionised treatment other malignancies including melanoma renal cell carcinoma over past decade, they only gained foothold years. This article reviews existing evidence ICIs as novel option. It also looks ongoing trials inhibition both perioperative advanced setting, combination targets HER2+. Other investigational therapies chimeric antigen T-cell (CAR-T) anti-T immunoreceptor immunoglobulin tyrosine-based inhibitory motif domain (anti-TIGIT) are considered, reviewing building alternative currently under investigation GC, fibroblast 2b (FGFR2b) claudin 18.2 amongst others. These evolving represent brave new world intervention potential transform outcomes patients internationally.
Язык: Английский
Процитировано
5
Life Sciences, Год журнала: 2023, Номер 328, С. 121866 - 121866
Опубликована: Июнь 16, 2023
Язык: Английский
Процитировано
4
Experimental Cell Research, Год журнала: 2019, Номер 382(2), С. 111487 - 111487
Опубликована: Июнь 28, 2019
Язык: Английский
Процитировано
7